{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024480","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.270316+00:00","generated_at":"2026-06-21T22:31:43.630391+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"aTyr Pharma reports Q3 2022 cash $79.6M; Phase 3 sarcoidosis study initiated","bullets":["Ended Q3 2022 with $79.6M in cash, restricted cash, cash equivalents and investments.","First patient dosed in EFZO-FIT Phase 3 study of efzofitimod for pulmonary sarcoidosis; targets 264 subjects.","Will not initiate Phase 1 for ATYR2810 this year; pursuing external non-dilutive funding.","FDA granted Fast Track designation for efzofitimod in systemic sclerosis-associated ILD.","Q3 R&D expenses $9.9M, G&A $3.6M; 29.0M shares outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024480","json":"https://secwatch.observer/filing/0000950170-22-024480.json","markdown":"https://secwatch.observer/filing/0000950170-22-024480.md","text":"https://secwatch.observer/filing/0000950170-22-024480.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017022024480/0000950170-22-024480-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017022024480/life-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:31:43.630391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"754d7f835767e830be577cb7643b304267e8aaa4","claim":"aTYR PHARMA INC reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339970/000095017022024480/0000950170-22-024480-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}